Molindone: effects in pigeons responding under conditional discrimination tasks

The Cognitive Effect Profiles of NMDA Receptor Modulating Drugs are Resolvable If Stimulus Complexity Is Varied in a Number Discernment Task

Number discernment is at the heart of task accuracy for laboratory animals performing Fixed Consecutive Number (FCN) operant tasks. Narrow-limit FCN tasks, in particular, are useful for measuring working memory in rat subjects because performance efficacy, which is set up to concord with food delivery, depends on a fairly precise quantification of cues generated by the rat's ongoing behavior. Reported here is a behavioral pharmacology study that utilized a group of overtrained and FCN-schedule-compliant rats injected in a randomized series of testing sessions with different types of N-methyl-D-aspartate (NMDA) receptor modulating drugs. Modifications made to the narrowlimit FCN schedule permitted a simultaneous measure of druginduced compromises in subjects' sensory integrative or motor coordinating capabilities. This highly sensitive model implicated the intrachannel and the glutamate recognition NMDA receptor binding sites as prime mediators of NMDA antagonist associated memory impairments because drugs acting at the mentioned sites lowered counting efficacy without altering sensorimotor function.

Effects of chlorpromazine on rats' acquisition of lever-press responding with immediate and delayed reinforcement

The effects of chlorpromazine (0, 2, 6, and 10 mg/kg) on the acquisition of lever-press responding by rats were examined under conditions where reinforcement (water delivery) was immediate or delayed. Under the immediate reinforcement condition, water-deprived rats were exposed during 8-h sessions to a fixed-ratio 1 (FR 1) schedule of water delivery without prior autoshaping or hand shaping. Under the delayed reinforcement condition, similar rats were exposed to a tandem FR 1 fixed-time 8-s schedule of water delivery. A different squad of eight rats was exposed to each delay condition and drug dose. For all subjects, responses on one lever produced water and responses on a second lever had no programmed consequences. Regardless of whether reinforcement was immediate or delayed, chlorpromazine reduced in dose-dependent fashion the mean number of operative-lever responses emitted, which suggests that the drug interfered with learning. At all chlorpromazine doses except 10 mg/kg, substantially more operative-lever than inoperative-lever responding occurred, indicating that the operant response was acquired. Chlorpromazine at 2 and 6 mg/kg disrupted the acquisition of stimulus control by the operative lever when reinforcement was delayed, but not when it was immediate. At 10 mg/kg, most subjects did not acquire lever-pressing regardless of whether they were exposed to the immediate or delayed reinforcement procedure. Procedures similar to those used in the present study appear to provide a reasonable assay for examining how drugs affect the initial behavioral effects of immediate and delayed reinforcement, and may merit further investigation.

Triazolam in Alzheimer's disease: pilot study on sleep and memory effects

We examined the effects on sleep and memory of a nighttime dose of triazolam, 0.125 mg, in seven subjects with Alzheimer's disease (AD) who were reported by caregivers to be frequently up at night. Subjects were admitted to an intermediate care hospital ward for the 8-day ABA design protocol (placebo baseline-drug-placebo washout). Drug or placebo was given each evening at 2100 h. Sleep was assessed with a wrist-worn activity monitor. Memory was evaluated using a computerized delayed-matching-to-sample (DMTS) task administered at 0800 and 2130 h. Triazolam had no significant effects on total sleep time at night, latency to sleep onset, number of arousals, or time asleep during the day. DMTS performance was significantly worse at night compared to morning during baseline, but there were no significant drug effects. Our results suggest the standard geriatric dose of triazolam, 0.125 mg, may not be an effective hypnotic in AD patients with disrupted sleep, but neither does it substantially worsen the recent memory deficits of AD.

Beta-amyloid(1-40) effects on behavior and memory

Beta amyloid 1-40 is a primary protein in plaques found in the brains of patients with Alzheimer's disease. There is evidence that unaggregated soluble beta-amyloid may be neurotoxic and may have behavioral effects on some types of memory. In the current study, the 1-40 fragment of beta-amyloid protein (beta A4), or vehicle, was bilaterally injected into the rostral hippocampus of rats performing under stable food-maintained schedules of reinforcement or under a delayed conditional discrimination procedure. Under the first procedure, rats were trained to stability under a multiple fixed interval 15 s, fixed ratio 30 reinforcement schedule. This reinforcement schedule has proven sensitive to low-dose drug effects. Acute bilateral hippocampal beta A4 (1.0, 2.0 and 3.0 microliters of 10(-3) M) administration did not significantly alter responding, compared to vehicle, under either reinforcement condition. Following the acute single-injection regimen, rats were administered chronic daily beta A4 (1 microliter of 10(-3) M), bilaterally, for 15 days. No significant changes in lever-pressing performance were observed during the chronic injection regimen, but performance declined significantly 30 days after termination of the chronic daily regimen. Histological examination revealed three of six rats showed positive reactions under Thioflavin S staining in and around the area of cannulae termination. The second assessment employed a delayed conditional discrimination procedure to evaluate the effects of intrahippocampal injections of beta A4 on short-term working memory. This conditional discrimination procedure assesses appropriate responding, dependent on a previously presented stimulus, after delays of various lengths have been imposed between the stimulus and the response opportunity.(ABSTRACT TRUNCATED AT 250 WORDS)

Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety

In view of the cholinergic deficits present in patients with Alzheimer's disease (AD), a widely investigated treatment strategy for the cognitive deficits in AD is cholinergic stimulation. Although nicotinic cholinergic receptor binding has been demonstrated to be deficient in the AD brain, the predominant theoretical and therapeutic focus to date has been on muscarinic cholinergic receptors and systems. The purpose of the present study was to evaluate the effects of sustained nicotine administration on behavior, cognition, and physiology. A double-blind placebo-controlled trial was conducted in which six patients with probable AD were exposed to 7, 8, and 7 days of placebo, nicotine, and washout, respectively. Daily sessions evaluating learning, memory, and behavior were conducted. Global cognitive functioning, rest and activity levels, cardiac activity, and blood levels were also measured. Findings included improved learning during the nicotine condition, which persisted throughout washout. Memory, behavior, and global cognition were not significantly affected. Sustained administration of nicotine appeared to be safe, although sleep showed a significant decrease.

Effects of neuropeptide Y on short-term memory

Neuropeptide Y (NPY) is a ubiquitous neuropeptide which may modulate several behavioral and physiological phenomena. Among other behavioral effects, NPY has been shown to enhance memory processes in mice. The current study employed a delayed conditional discrimination procedure to evaluate the effects of intracerebroventricular injections of NPY on short-term working memory. This conditional discrimination procedure assesses appropriate responding, based on a previously presented stimulus, after various delays have been imposed between the stimulus and the opportunity for a response. Delay values ranged from 0.01 s to 30 s. NPY decreased accuracy across delay values in a dose-dependent manner. The two highest doses of NPY (3.0 and 10.0 micrograms) significantly decreased accuracy. Doses lower than those used in the current study have shown facilitation of memory processes under avoidance procedures in mice. Intraperitoneal naloxone (3.0 mg/kg), an opioid antagonist, completely blocked NPY's memory degrading effects. Procedural differences may account for NPY-induced degradation of short-term working memory under delayed conditional discrimination and previous reports of NPY's enhancement of retention under shock avoidance procedures.